Aficamten

Aficamten is a leading cardiac myosin inhibitor API and research compound at the forefront of hypertrophic cardiomyopathy drug development. With an IC₅₀ of 1.4 μM against cardiac myosin , Aficamten provides targeted inhibition of cardiac hypercontractility — the underlying pathophysiological mechanism of HCM. In research and development contexts, Aficamten is supplied with comprehensive characterization data for preclinical studies, analytical method development, and quality control applications. The unique molecular architecture of Aficamten enables selective cardiac myosin inhibition with a projected human half-life suitable for once-daily dosing , representing a significant advance over earlier myosin inhibitors. Aficamten has been evaluated in clinical trials under the brand name MyQorzo®, demonstrating its therapeutic potential for patients with hypertrophic cardiomyopathy .

Product Parameters

Product Advantages

 Potent Cardiac Myosin Inhibitor

Aficamten inhibits cardiac myosin with an IC₅₀ of 1.4 μM , reducing cardiac hypercontractility — the hallmark of hypertrophic cardiomyopathy.

 Next-Generation Design

Aficamten was designed to provide a projected human half-life appropriate for once-daily dosing, reaching steady state within two weeks, with no substantial cytochrome P450 induction or inhibition .

 Favorable Pharmacokinetics

Aficamten demonstrates moderate oral bioavailability across preclinical species (mouse 98%, rat 55–79%, dog 45%, monkey 41%) with a clear PK/PD relationship and wide therapeutic window .

 High-Purity Research Compound

Cosperpharm supplies Aficamten at ≥98% purity with full characterization data, suitable for in vitro and in vivo research applications.

 Clinical-Stage Compound

Aficamten has been evaluated in clinical trials under the brand name MyQorzo®, demonstrating its therapeutic potential for HCM patients .

Storage Conditions

Store Aficamten as a powder at –20°C for up to 3 years or at 4°C for up to 2 years . For solution storage in DMSO, aliquot and store at –80°C for up to 6 months or at –20°C for up to 1 month. Protect from light and moisture.

Handling precautions: Use only in a fume hood. Wear chemical-resistant gloves, safety goggles, and a lab coat. Avoid generating dust or aerosols. Refer to the Safety Data Sheet (SDS) for complete safety information.

Product Quality Assurance

Cosperpharm has established a comprehensive quality assurance system for Aficamten that meets the rigorous expectations of research customers:

Thorough analytical characterization. Each batch undergoes multi‑technique analytical release testing: HPLC purity (≥98%), chiral purity verification, appearance verification, and identity confirmation.

Full batch traceability. From synthesis through purification and final packaging, every step is fully documented and traceable.

Documentation ready for research use. Every shipment includes a Certificate of Analysis (COA) with batch‑specific purity data and identification information.

Contact Us

Cosperpharm is your trusted partner for Aficamten — from milligram quantities for screening to gram quantities for preclinical studies. Contact our team today for pricing, documentation, or technical support.